b'Dr Shaun Robertson Dr Shaun Robertson took part in the 2022 Biofilms ICURe Sprint. After completing the programme Dr Robertson was awarded funding to transform his solution into a spin-out called MiDx. MiDx provides an innovative testing solution by combining our precise, rapid, microbial identification technology with a deep understanding of the unique challenges faced by those with cystic fibrosis. The spin-out aims to enhance the quality of life for patients and contribute to a future where early, accurate microbial identification becomes a cornerstone in the management of this complex condition.MiDxs goal is to provide accurate and timely diagnosticDr Shaun Robertson and Dr Helen Barr.solutions for microbial infections, improving patient outcomes and quality of life across various healthcare settings.MiDxs Rapid Pseudomonas aeruginosa detection (RPaD) lateral flow device is currently undergoing performance evaluation in a clinical study: Understanding novel Point of Care testing of Alkyl Quinolones for Pseudomonas aeruginosa (UnPAQ)a feasibility study. This study is led by University of Nottingham Associate Professor, Nottingham University Hospital Trust Honorary Clinical Consultant and MiDx CMO Dr Helen Barr.All of our case studies can be found on thePROJECTS ANDProjects and Case Studies page on our website. CASE STUDIES25 2525'